219 related articles for article (PubMed ID: 30276727)
1. Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany.
Krause A; Aries PM; Berger S; Fiehn C; Kellner H; Lorenz HM; Meier L; Müller GA; Müller-Ladner U; Schwarting A; Tony HP; Peters MA; Wendler J
Z Rheumatol; 2019 Nov; 78(9):881-888. PubMed ID: 30276727
[TBL] [Abstract][Full Text] [Related]
2. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
Torrente-Segarra V; Acosta Pereira A; Morla R; Ruiz JM; Clavaguera T; Figuls R; Corominas H; Geli C; Roselló R; de Agustín JJ; Alegre C; Pérez C; García A; Rodríguez de la Serna A
Reumatol Clin; 2016; 12(6):319-322. PubMed ID: 26831256
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan.
Wang KC; Liao HT; Chen WS; Lai CC; Chou CT; Chen MH; Tsai CY
Int J Rheum Dis; 2019 May; 22(5):860-868. PubMed ID: 30761753
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
Park W; Suh CH; Shim SC; Molina FFC; Jeka S; Medina-Rodriguez FG; Hrycaj P; Wiland P; Lee EY; Shesternya P; Kovalenko V; Myasoutova L; Stanislav M; Radominski S; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Yoo DH
BioDrugs; 2017 Aug; 31(4):369-377. PubMed ID: 28600696
[TBL] [Abstract][Full Text] [Related]
8. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
[TBL] [Abstract][Full Text] [Related]
9. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
10. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
[TBL] [Abstract][Full Text] [Related]
11. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
12. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
[TBL] [Abstract][Full Text] [Related]
13. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Finckh A; Ciurea A; Brulhart L; Möller B; Walker UA; Courvoisier D; Kyburz D; Dudler J; Gabay C;
Ann Rheum Dis; 2010 Feb; 69(2):387-93. PubMed ID: 19416802
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.
Burmester G; Nüsslein H; von Hinüber U; Detert J; Richter C; Kumke T; Leunikava I; Lendl U; Fricke D; Müller-Ladner U
Clin Exp Rheumatol; 2019; 37(5):842-851. PubMed ID: 30873942
[TBL] [Abstract][Full Text] [Related]
15. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients.
Wendler J; Burmester GR; Sörensen H; Krause A; Richter C; Tony HP; Rubbert-Roth A; Bartz-Bazzanella P; Wassenberg S; Haug-Rost I; Dörner T
Arthritis Res Ther; 2014 Mar; 16(2):R80. PubMed ID: 24670196
[TBL] [Abstract][Full Text] [Related]
17. Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.
Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge EM; Pavelka K; Gabay C; Scherer A; Nordström D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Hernández MV; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
J Rheumatol; 2017 Feb; 44(2):162-169. PubMed ID: 28089978
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Emery P; Gottenberg JE; Rubbert-Roth A; Sarzi-Puttini P; Choquette D; Taboada VM; Barile-Fabris L; Moots RJ; Ostor A; Andrianakos A; Gemmen E; Mpofu C; Chung C; Gylvin LH; Finckh A
Ann Rheum Dis; 2015 Jun; 74(6):979-84. PubMed ID: 24442884
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]